Log in

LogicBio Therapeutics Stock Forecast, Price & News

+0.38 (+5.77 %)
(As of 11/30/2020 12:00 AM ET)
Today's Range
Now: $6.97
50-Day Range
MA: $6.03
52-Week Range
Now: $6.97
Volume113,298 shs
Average Volume104,741 shs
Market Capitalization$221.55 million
P/E RatioN/A
Dividend YieldN/A
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. It has a partnership with Children's Medical Research Institute to develop new viral vectors; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop new genome editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company was founded in 2014 and is headquartered in Lexington, Massachusetts.

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.79 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:LOGC



Sales & Book Value

Annual SalesN/A
Book Value$1.84 per share


Net Income$-40,130,000.00


Market Cap$221.55 million
Next Earnings Date3/15/2021 (Estimated)
OptionableNot Optionable
+0.38 (+5.77 %)
(As of 11/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LOGC News and Ratings via Email

Sign-up to receive the latest news and ratings for LOGC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

LogicBio Therapeutics (NASDAQ:LOGC) Frequently Asked Questions

How has LogicBio Therapeutics' stock price been impacted by COVID-19?

LogicBio Therapeutics' stock was trading at $7.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LOGC shares have decreased by 1.0% and is now trading at $6.97.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of LogicBio Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LogicBio Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for LogicBio Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than LogicBio Therapeutics?

Wall Street analysts have given LogicBio Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but LogicBio Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is LogicBio Therapeutics' next earnings date?

LogicBio Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for LogicBio Therapeutics

How were LogicBio Therapeutics' earnings last quarter?

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) issued its quarterly earnings data on Monday, November, 9th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.07.
View LogicBio Therapeutics' earnings history

What price target have analysts set for LOGC?

2 brokers have issued 12 month target prices for LogicBio Therapeutics' shares. Their forecasts range from $20.00 to $20.00. On average, they expect LogicBio Therapeutics' stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 186.9% from the stock's current price.
View analysts' price targets for LogicBio Therapeutics

Are investors shorting LogicBio Therapeutics?

LogicBio Therapeutics saw a increase in short interest during the month of October. As of October 30th, there was short interest totaling 535,900 shares, an increase of 23.5% from the October 15th total of 433,900 shares. Based on an average daily trading volume, of 182,900 shares, the days-to-cover ratio is presently 2.9 days. Approximately 2.8% of the shares of the company are short sold.
View LogicBio Therapeutics' Short Interest

Who are some of LogicBio Therapeutics' key competitors?

What other stocks do shareholders of LogicBio Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), Acceleron Pharma (XLRN), Stoke Therapeutics (STOK), Precision BioSciences (DTIL), Micron Technology (MU), Homology Medicines (FIXX) and II-VI (IIVI).

Who are LogicBio Therapeutics' key executives?

LogicBio Therapeutics' management team includes the following people:
  • Mr. Frederic Chereau M.B.A., Pres, CEO & Director (Age 53, Pay $632.9k)
  • Dr. Mark A. Kay, Independent Co-Founder & Director (Age 62, Pay $102.5k)
  • Dr. Leszek Lisowski Ph.D., Co-Founder
  • Dr. Adi Barzel Ph.D., Co-Founder
  • Mr. Matthias B. Jaffé, Chief Financial Officer (Age 52)
  • Dr. Kyle Chiang Ph.D., Chief Operating Officer
  • Dr. Matthias Hebben, Global VP & Head of Technology Devel.
  • Mr. Brian Luque, Associate Director of Investor Relations
  • Dr. Daniel J. Gruskin M.D., Sr. VP & Head of Clinical Devel.

When did LogicBio Therapeutics IPO?

(LOGC) raised $77 million in an initial public offering on Friday, October 19th 2018. The company issued 5,800,000 shares at a price of $12.50-$14.00 per share. Jefferies, Barclays and William Blair acted as the underwriters for the IPO and Chardan was co-manager.

What is LogicBio Therapeutics' stock symbol?

LogicBio Therapeutics trades on the NASDAQ under the ticker symbol "LOGC."

Who are LogicBio Therapeutics' major shareholders?

LogicBio Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Samlyn Capital LLC (2.43%), BlackRock Inc. (2.35%), JPMorgan Chase & Co. (0.97%), Jefferies Group LLC (0.11%), FNY Investment Advisers LLC (0.03%) and BNP Paribas Arbitrage SA (0.01%). Company insiders that own LogicBio Therapeutics stock include Bioscience Plc Arix and Orbimed Advisors Llc.
View institutional ownership trends for LogicBio Therapeutics

Which major investors are selling LogicBio Therapeutics stock?

LOGC stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., and Samlyn Capital LLC.
View insider buying and selling activity for LogicBio Therapeutics

Which major investors are buying LogicBio Therapeutics stock?

LOGC stock was acquired by a variety of institutional investors in the last quarter, including Jefferies Group LLC, BlackRock Inc., FNY Investment Advisers LLC, and BNP Paribas Arbitrage SA.
View insider buying and selling activity for LogicBio Therapeutics

How do I buy shares of LogicBio Therapeutics?

Shares of LOGC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is LogicBio Therapeutics' stock price today?

One share of LOGC stock can currently be purchased for approximately $6.97.

How big of a company is LogicBio Therapeutics?

LogicBio Therapeutics has a market capitalization of $221.55 million. The company earns $-40,130,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis. LogicBio Therapeutics employs 41 workers across the globe.

What is LogicBio Therapeutics' official website?

The official website for LogicBio Therapeutics is www.logicbio.com.

How can I contact LogicBio Therapeutics?

LogicBio Therapeutics' mailing address is 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421. The company can be reached via phone at 617-245-0399 or via email at [email protected]

This page was last updated on 12/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.